Pandemic preparedness typically follows the same pattern: a virus emerges, scientists develop a vaccine against it, production begins with months of delay. The University of Cambridge and its spinoff DIOSynVax want to break this cycle. Their vaccine was not designed against a single known virus, but against an entire viral family, including pathogens found only in bats. The first human study, results published June 5, 2026, provides early evidence the approach works.
What a sarbecovirus is and why it remains dangerous
Sarbecoviruses are a genus of betacoronaviruses that includes SARS-CoV-2, the cause of the COVID-19 pandemic, and SARS-CoV-1, which killed roughly 800 people from 2002 to 2003. Southeast Asian and Chinese bat colonies are known to harbor dozens of additional sarbecoviruses that could potentially jump to humans. A targeted vaccine against one member of this family offers no reliable protection against the others.
This is exactly the problem DIOSynVax aims to solve. Cambridge's spinoff uses machine learning to analyze genetic sequence data from all known sarbecoviruses and distill a single "super-antigen," an artificial protein representing features conserved across the entire viral family and thus resistant to rapid mutation by any single virus. The antigen itself is not a naturally occurring protein but a computational design that does not exist in nature.
How the trial unfolded and what it showed
39 healthy volunteers aged 18 to 50 participated in the Phase 1 trial. The vaccine was administered as a DNA vaccine using a needle-free microfluidic jet injector that delivers genetic material directly into the skin. Result: no serious adverse events. All participants developed immune responses effective not only against SARS-CoV-2 and SARS-CoV-1, but also against related bat coronaviruses never seen in humans.
Professor Jonathan Heeney, who leads the research team, stated in a Cambridge press release: "We have shifted vaccine development from reactive to future-ready. Our vaccines will continue to protect even as viruses change." This is the first time a vaccine designed entirely through AI and computer simulation has been tested in humans, according to researchers. The project was supported by Innovate UK, the British innovation agency.
In comparison: What universal vaccine projects have achieved
Universal flu vaccines have been attempted for decades. The principle is identical to DIOSynVax: one antigen effective against all variants of a viral family, without annual adaptation. BioNTech and Pfizer's classic COVID mRNA platform could be developed within months but offered reliable protection only for the original SARS-CoV-2 and its closest variants. Protection against genetically distant bat sarbecoviruses is not documented.
The Coalition for Epidemic Preparedness Innovations (CEPI) has set a goal of delivering a ready-to-use vaccine candidate within 100 days of a new pandemic outbreak. This requires the basic platform to already exist and be validated. A broadly protective sarbecovirus vaccine that passes Phase 1 could be one building block for this approach, though DIOSynVax has not yet announced a partnership with CEPI for this candidate.
Munich-based Ethris published a preclinical study simultaneously describing an mRNA version of the same DIOSynVax antigen, which showed similar broad-protection results in animal testing. mRNA can be manufactured faster and in larger quantities than DNA. Combining both platforms could become important for mass production.
Three conditions for the path to approval
Phase 1 demonstrates safety and basic efficacy. Realistic timelines to an approved vaccine are ten to twelve years from this development stage. Three conditions must be met.
First, a Phase 2 trial with several hundred participants proving the observed immune responses are clinically relevant, meaning they actually prevent infection. This requires either a new sarbecovirus outbreak in humans or a controlled challenge study. Second, a Phase 3 trial with tens of thousands of participants to statistically prove efficacy. Third, production capacity for DNA vaccines must be expanded. The platform is currently less scalable than mRNA or classical inactivated vaccines. If all three conditions are met and no unexpected safety signals emerge, DIOSynVax would be the first vaccine explicitly designed for pathogens that have not yet reached humans.